drugset / Trial / NCT06109181
Gene Therapy for ACM Due to a PKP2 Pathogenic Variant
NaSequentialOpen-labelTreatment
Summary
This is a Phase 1/2, first-in-human, open-label, intravenous, dose-escalating, multicenter trial that is designed to assess the safety and tolerability of LX2020 in adult patients with PKP2-ACM
Timeline
- Start
- 2024-02-29
- Primary completion
- 2026-12
- Completion
- 2027-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LX2020 | Gene therapy (AAV / viral vector) | 2e+13 unknown | Intravenous |